Categories Earnings, LATEST, Retail

Molson Coors Brewing Company (NYSE: TAP): Q3 2019 Earnings Snapshot

– Molson Coors Brewing Company (NYSE: TAP) reported underlying earnings of $1.48 per share for the third quarter of 2019, vs. $1.48 per share expected.

– Total revenues decreased 3.2% annually to $2.84 billion in the September-quarter, vs. $2.87 billion expected

Molson Coors Brewing Company (NYSE: TAP): Q3 2019 Earnings Snapshot

– On a reported basis, Molson reported a net loss of $402.8 million or $1.86 per share, compared to profit of $338.3 million or $1.56 per share last year

– Expects underlying free cash flow of $1.4 billion, plus or minus 10%, for fiscal 2019; sees capital spending of approximately $700 million, plus or minus 10%

– Expects net sales revenue to be flat to low-single digit decrease, on a constant currency basis, in fiscal 2020; expects underlying free cash flow of $1.1 billion, plus or minus 10%, for 2020

– Announced revitalization plan to achieve consistent top-line growth by improving efficiency and unlocking resources to reinvest in the business

— Molson Coors shares dropped early Wednesday, following the earnings report, after closing the previous session higher

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings

After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform

What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings

Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top